Eli Lilly and Company (FRA:LLY)
Germany · Delayed Price · Currency is EUR | Market Cap | 773.54B +10.9% |
| Revenue (ttm) | 62.66B +47.4% |
| Net Income | 21.92B +127.6% |
| EPS | 24.42 +129.1% |
| Shares Out | n/a |
| PE Ratio | 35.28 |
| Forward PE | 27.21 |
| Dividend | 5.37 (0.62%) |
| Ex-Dividend Date | Feb 13, 2026 |
| Volume | 1 |
| Average Volume | 331 |
| Open | 865.40 |
| Previous Close | 870.40 |
| Day's Range | 865.40 - 868.60 |
| 52-Week Range | 537.40 - 968.10 |
| Beta | n/a |
| RSI | 63.45 |
| Earnings Date | Apr 30, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
Charts to Watch: SPX All-Time High, CIFR & LLY Breakouts
@CharlesSchwab's Kevin Horner breaks down key market charts as the S&P 500 (SPX) taps new record highs, backed by investors defending the 10-day SMA. In stock movers, he highlights notable technical s...
Eli Lilly launches Alzheimer's drug Donanemab in India
U.S.-based drugmaker Eli Lilly on Wednesday launched its Alzheimer's drug Lormalzi, also known as Donanemab, in India.
Eli Lilly discloses results on Foundayo and lower-dose Zepbound
The company states: “Eli Lilly (LLY) announced detailed results from two late-phase trials showing that people with obesity maintained their weight loss long term with either Foundayo or lower-dose Ze...
Patients don't regain much weight switching from injections to Lilly's weight-loss pill, study finds
Eli Lilly said on Tuesday that patients in a late-stage trial who had been taking an injectable GLP-1 medication for over a year did not regain significant weight after switching to its new weight-l...
Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials
In ATTAIN-MAINTAIN, participants who transitioned from a maximum tolerated dose (MTD) of Wegovy (semaglutide) to Foundayo maintained all but 0.9 kg of their previously achieved weight loss on average ...
In honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantries
Through charitable support of HATCH, United Way Worldwide, United Way of Central Indiana and the Pacers Foundation, the initiative supports efforts to expand access to protein-rich food across communi...
Eli Lilly (LLY) Invests Another $4.5 Billion in U.S. Manufacturing as Weight-Loss Drugs Take Off
The pharma giant is looking to maintain its market share lead.
Roche receives CE Mark for Elecsys pTau217
Roche (RHHBY) announced that it has received CE Mark for Elecsys pTau217, a blood test developed in collaboration with Eli Lilly and Company (LLY) and designed to measure the phosphorylated…
Exclusive: Lilly halts India obesity awareness campaign after regulatory scrutiny, seeks rules clarity
Eli Lilly paused its obesity awareness campaign in India after the nation's drugs regulator warned the company it could violate rules against advertising prescription medicines to consumers even indi...
NYSE Content Update: Eli Lilly to Celebrate 150 Years of Scientific Innovation
NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, May 11, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NY...
Why Eli Lilly’s Rival Novo Nordisk (NVO) Stock Is Rising Today, 5/11/26
Shares in Novo Nordisk ($NVO), the Danish pharma rival to U.S.-based Eli Lilly ($LLY), rose roughly 3% in Monday’s pre-market trading. This comes as the Wegovy weight-loss drug maker is…
AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth
Healthcare is regaining momentum as innovation—especially AI‑driven drug discovery—creates new growth opportunities, according to Shivani Vohra. She points to obesity treatments from Eli Lilly (LLY) a...
Lilly's obesity pill tops 7,000 prescriptions in fourth week, signals modest uptake
Eli Lilly's new oral weight-loss drug, Foundayo, was prescribed 7,335 times in the U.S. in the fourth week, a modest uptake compared to rival Novo Nordisk's Wegovy pill, analysts said.
Eli Lilly price target raised to $1,235 from $1,183 at Guggenheim
Guggenheim analyst Seamus Fernandez raised the firm’s price target on Eli Lilly (LLY) to $1,235 from $1,183 and keeps a Buy rating on the shares. The firm updated its model…
Novo (NVO) and Lilly (LLY) Stocks Jump as Weight-Loss Pills Reveal Monster Market Potential
Shares of Novo Nordisk ($NVO) and Eli Lilly & Co. ($LLY), two of the world’s largest drugmakers, rose slightly on Wednesday after data showed strong demand for their new oral…
Novo and Lilly gain on signs weight-loss pills could expand the market
Early data from weight-loss pills are lifting shares in Novo Nordisk and Eli Lilly as investors bet that easier-to-take drugs could expand the market to millions more patients and help counter pricin...
Heard on the Street: The fastest-growing part of the weight-loss market—and perhaps the most underappreciated driver for both Novo Nordisk and Lilly—is outside the U.S.
While investors obsess over uptake of GLP-1 pills in the U.S., international sales are just as important.
Lilly commits additional $4.5 billion across Indiana manufacturing sites
Eli Lilly said on Wednesday it would commit an additional $4.5 billion investment across two of its three sites in Indiana, bringing the company's total capital expansion commitments in the...
Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility
Lilly's capital commitments to expand manufacturing in its home state now total $21 billion since 2020 Lilly Lebanon Advanced Therapies opens as company's first dedicated genetic medicine manufacturin...
Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly.
Novo Nordisk stock rose as it raised its guidance on the back of the strong performance of its weight-loss pill.
The Billion-Dollar Women's Health Market Driving A New Endometriosis Focus
The commercial success of GLP-1 therapies has reshaped the economics of modern pharmaceuticals. What began as a treatment pathway for type 2 diabetes and obesity has evolved into one of the most lucra...
Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years
In LUCENT-3, more than 60% of patients who achieved disease clearance at one year maintained it after four years of continuous Omvoh treatment Disease clearance is a high clinical bar in UC requiring ...
Lilly declares second-quarter 2026 dividend
INDIANAPOLIS, May 4, 2026 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2026 of $1.73 per share on outstanding common st...
FDA Reports Liver Failure in Patient Taking Lilly's Foundayo
The Food and Drug Administration has recorded two ‘serious' cases in patients taking Eli Lilly's weight-loss pill.
Eli Lilly and Company Transcript: AGM 2026
The meeting covered director elections, management and shareholder proposals, and strong financial results, including a 45% revenue increase and major product launches. Shareholder proposals on board independence and lobbying transparency did not pass. Dividend growth and manufacturing expansion were highlighted.